مرکز قلب تهران

دکتر آزیتا حاج حسین طلاساز

دکتر آزیتا حاج حسین طلاساز متخصص دارو سازي باليني

 

Tehran Heart Center
Tehran University of Medical Sciences
a-talasaz@tums.ac.ir



PROFESSIONAL TRAINING                  

Fellowship of Cardiology in Critical Care                  Sep 2014 to Sep 2016
Tehran Heart Center, Tehran, Iran
Supervisor: Mojtaba Mojtahedzadeh, Pharm D
Director: Abbasali Karmi, MD
                    

EDUCATION    

                                    
PhD in Clinical Pharmacy                                    Sep 2007 to April 2011
Shahid Beheshti University of Medical Sciences
Tehran, Iran               


Doctor of Pharmacy                                                                 Sep 2000 to Oct 2006    
Tehran University of Medical Sciences
Tehran, Iran                


CERTIFICATIONS                              

Board Certified Pharmacotherapy Specialist              Dec 2010 to Present
Added Qualifications in Cardiology                                         Dec 2014 to Present
Board Certified Cardiology Pharmacotherapist                        Dec 2018 to Present
                    

PROFESSIONAL EXPERIENCE                        

Associate Professor of Clinical Pharmacy               May 2016 to Present    
Department of Clinical Pharmacy
School of Pharmacy
Tehran University of Medical Sciences
Tehran, Iran


Assistant Professor of Clinical Pharmacy                                Nov 2011-May 2016
Department of Clinical Pharmacy
School of Pharmacy
Tehran University of Medical Sciences
Tehran, Iran


Clinical Pharmacist                                                                Nov 2011 to Present  
Tehran Heart Center
Tehran University of Medical Sciences
Tehran, Iran
                    

RESEARCH EXPERIENCE

                                
1.Talasaz AH, Shaseb E, Tohidi M, Hadaegh F, Ariannejad H, Abbasinazari M. Effects of Parenteral Vitamin D on the Biomarkers of the Endothelial Function in Patients with Type 2 Diabetes and Ischemic Heart Disease: A Randomized Clinical Trial. Iran J Pharm Res. 2018;17(Suppl2):187-194.
2.Daie M,  Talasaz AH, Karimi A, Gholami K, Salehiomran A, Ariannejad H, Jalali A. Relationship between Vitamin D Levels and the Incidence of Post Coronary Artery Bypass Graft Surgery Atrial Fibrillation. J Tehran Heart Cent. 2018 Oct;13(4):159-165.
3.Ghaeli P, Solduzian M, Vejdani S, Talasaz AH. Comparison of the Effects of Melatonin and Oxazepam on Anxiety Levels and Sleep Quality in Patients With ST-Segment-Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial. Ann Pharmacother. 2018 Oct;52(10):949-955. doi: 10.1177/1060028018776608. Epub 2018 May 11.
4.Jenab Y, Kassaian E, Pourhosseini HR, Salarifar M, Jalali A, Talasaz AH. Two-year Follow-up of Patients With Unstable Angina/Non-ST Segment Elevation Myocardial Infarction Undergoing Early Invasive Strategy: Predictors of Normal or Near-Normal Coronary Angiography and Mortality. Crit Pathw Cardiol. 2018 Mar;17(1):47-52. doi: 10.1097/HPC.0000000000000108.
5.Nozari Y, Eshraghi A, Talasaz AH, Bahremand M, Salamzadeh J, Salarifar M, Pourhosseini H, Jalali A, Mortazavi SH. Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center. Am J Cardiovasc Drugs. 2018 Jun;18(3):213-221. doi: 10.1007/s40256-017-0258-8.
6.Ghaffary S, Ghaeli P, Talasaz AH, Karimi A, Noroozian M, Salehiomran A, Jalali A. Effect of memantine on post-operative cognitive dysfunction after cardiac surgeries: a randomized clinical trial. Daru. 2017 Nov 21;25(1):24. doi: 10.1186/s40199-017-0190-0.
7.Mohammadi M,  Talasaz AH, Alidoosti M, Pour Hosseini HR, Gholami K, Jalali A, Aryannejad H. Nephroprotective Effects of L-Carnitine against Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Open-Labeled Clinical Trial. J Tehran Heart Cent. 2017 Apr;12(2):57-64.
8.Alemzadeh-Ansari MJ, Hosseini SK, Talasaz AH, Mohammadi M, Tokaldani ML, Jalali A, Pourhosseini H. Effect of High-Dose Allopurinol Pretreatment on Cardiac Biomarkers of Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial. Am J Ther. 2017 Nov/Dec;24(6):e723-e729. doi: 10.1097/MJT.0000000000000411.
9.Boroumand M, Pourgholi L, Goodarzynejad H, Ziaee S, Talasaz AH, Sotoudeh-Anvari M, Mandegary A. NQO1 C609T Polymorphism is Associated with Coronary Artery Disease in a Gender-Dependent Manner. Cardiovasc Toxicol. 2017 Jan;17(1):35-41. doi: 10.1007/s12012-015-9353-8.
10.Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, Shahmansouri N, Arjmandi-Beglar A, Talasaz AH, Salehiomran A, Forghani S, Akhondzadeh S: Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. The Journal of Alternative and Complementary Medicine 11/2017; 24(4)., DOI:10.1089/acm.2017.0173
11.Dastan F, Talasaz AH, Mojtahedzadeh M, Karimi A, Salehiomran A, Bina P, Jalali A. Randomized Trial of Carnitine for the Prevention of Perioperative Atrial Fibrillation. Semin Thorac Cardiovasc Surg. 2018 Spring;30(1):7-13. doi: 10.1053/j.semtcvs.2017.08.006.
12.Nikbakht M, Ahmadi F, Vaseghi G, Talasaz AH, Eshraghi A, Naderi J, Daneshmehr MA. The Role of N-Acetylcysteine in Platelet Aggregation and Reperfusion Injury in Recent Years. Curr Clin Pharmacol. 2017;12(2):83-91. doi: 10.2174/1574884712666170704145842. Review.
13.Ghelich Khan Z, Talasaz AH, Pourhosseini H, Hosseini K, Alemzadeh Ansari MJ, Jalali A. Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial. Clin Drug Investig. 2017 Sep;37(9):853-860. doi: 10.1007/s40261-017-0542-z.
14.Mohammadi M, Talasaz AH, Alidoosti M. Preventive effect of l-carnitine and its derivatives on endothelial dysfunction and platelet aggregation. Clin Nutr ESPEN. 2016 Oct;15:1-10. doi: 10.1016/j.clnesp.2016.06.009.
15.Pourgholi L, Goodarzynejad H, Mandegary A, Ziaee S, Talasaz AH, Jalali A, Boroumand M. Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicol Appl Pharmacol. 2016 Oct 15;309:37-43. doi: 10.1016/j.taap.2016.08.026.
16.Shaseb E, Tohidi M, Abbasinazari M, Khalili D, Talasaz AH, Omrani H, Hadaegh F. The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial. Acta Diabetol. 2016 Aug;53(4):575-82. doi: 10.1007/s00592-016-0843-3.
17.Eshraghi A, Talasaz AH, Salamzadeh J, Salarifar M, Pourhosseini H, Nozari Y, Bahremand M, Jalali A, Boroumand MA. Evaluating the Effect of Intracoronary N-Acetylcysteine on Platelet Activation Markers After Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction. Am J Ther. 2016 Jan-Feb;23(1):e44-51. doi: 10.1097/MJT.0000000000000309.
18.Gholami K, Talasaz AH, Entezari-Maleki T, Salarifar M, Hadjibabaie M, Javadi MR, Dousti S, Hamishehkar H, Maleki S. The Effect of High-Dose Vitamin D3 on Soluble P-Selectin and hs-CRP Level in Patients With Venous Thromboembolism: A Randomized Clinical Trial. Clin Appl Thromb Hemost. 2016 Jul;22(5):483-9. doi: 10.1177/1076029614568715.
19.Dianatkhah M, Ghaeli P,  Talasaz AH, Karimi A, Salehiomran A, Bina P, Jalali A, Ghaffary S, Shahmansouri N, Vejdani S. Evaluating the Potential Effect of Melatonin on the post-Cardiac Surgery Sleep Disorder. J Tehran Heart Cent. 2015 Jul 3;10(3):122-8.
20.Izadi Amoli A, Bozorgi A,  Talasaz AH, Salehi Omran A, Mortazavi SH, Jalali A, Nasirpour S, Jenab Y. Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery: A randomized, placebo-controlled trial. Am Heart J. 2015 Dec;170(6):1195-201. doi: 10.1016/j.ahj.2015.09.020.
21.Ghaeli P, Vejdani S, Ariamanesh A, Talasaz AH: Effect of Melatonin on Cardiac Injury after Primary Percutaneous Coronary Intervention: a Randomized Controlled Trial. Iranian journal of pharmaceutical research (IJPR) 09/2015; 14(3):851-5.
22.Ghaffary S,  Talasaz AH, Ghaeli P, Karimi A, Salehiomran A, Hajighasemi A, Bina P, Darabi S, Jalali A, Dianatkhah M, Noroozian M, Shahmansouri N. Association between Perioperative Parameters and Cognitive Impairment in Post-Cardiac Surgery Patients. J Tehran Heart Cent. 2015 Apr 3;10(2):85-92.
23.Dastan F,  Talasaz AH, Mojtahedzadeh M, Karimi A, Salehiomran A, Bina P, Jalali A, Aghaie Z. Potential Effect of L-Carnitine on the Prevention of Myocardial Injury after Coronary Artery Bypass Graft Surgery. J Tehran Heart Cent. 2015 Apr 3;10(2):74-9.
24.Eshraghi A, Talasaz AH, Salamzadeh J, Bahremand M, Salarifar M, Nozari Y, Jenab Y, Boroumand MA, Vaseghi G, Eshraghi N. Study of the possible medical and medication explanatory factors of angiographic outcomes in patients with acute ST elevation myocardial infarction undergoing primary percutaneous intervention. Adv Biomed Res. 2014 Sep 4;3:186. doi: 10.4103/2277-9175.140096. eCollection 2014.
25.Doosti A, Lotfi Y, Moossavi A, Bakhshi E, Talasaz AH, Hoorzad A. Comparison of the effects of N-acetyl-cysteine and ginseng in prevention of noise induced hearing loss in male textile workers. Noise Health. 2014 Jul-Aug;16(71):223-7. doi: 10.4103/1463-1741.137057.
26.Talasaz AH, Khalili H, Fahimi F, Jenab Y, Broumand MA, Salarifar M, Darabi F.Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial. Am J Cardiovasc Drugs. 2014 Feb;14(1):51-61. doi: 10.1007/s40256-013-0048-x.
27.Talasaz AH, Khalili H, Jenab Y, Salarifar M, Broumand MA, Darabi F. N-Acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-α serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction. Drugs R D. 2013 Sep;13(3):199-205. doi: 10.1007/s40268-013-0025-5.
28.Abbasinazari M,  Talasaz AH, Eshraghi A, Sahraei Z. Detection and management of medication errors in internal wards of a teaching hospital by clinical pharmacists. Acta Med Iran. 2013 Aug 7;51(7):482-6.
29.Khalili H, Dashti-Khavidaki S, Shahidi MR, Abdollahi A, Jafari S, Jahangard-Rafsanjani Z, Talasaz AH. Changes in gram negative microorganisms' resistance pattern during 4 years period in a referral teaching hospital; a surveillance study. Daru. 2012 Sep 10;20(1):28. doi: 10.1186/2008-2231-20-28.
30.Fahimi F, Kobarfard F, Salamzadeh J, Fakharian A, Abdolahi P, Talasaz AH, Pour HM, Baniasadi S, Masjedi M. The Bioavailability of Salbutamol in Urine via Volumatic and Nonvolumatic Valved Holding Chambers. World Allergy Organ J. 2011 Nov;4(11):179-83. doi: 10.1097/WOX.0b013e31823890f6. Epub 2011 Nov 18.
31.Talasaz AH. The potential role of clinical pharmacy services in patients with cardiovascular diseases. J Tehran Heart Cent. 2012 Spring;7(2):41-6.
32.Khalili H, Talasaz AH, Jenab Y, Salarifar M. Clinical characteristics and risk assessment of ST-segment elevation myocardial infarction patients of an Iranian referral center. J Cardiovasc Med (Hagerstown). 2012 Nov;13(11):708-15. doi: 10.2459/JCM.0b013e328356a3c6.
33.Khalili H, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to antiretroviral therapy among Iranian HIV/AIDS patients. Curr Clin Pharmacol. 2012 May;7(2):111-5.
34.Talasaz AH, Jahangard-Rafsanjani Z, Ziaie S, Fahimi F. Evaluation of the pattern of human albumin utilization at a university affiliated hospital. Arch Iran Med. 2012 Feb;15(2):85-7. doi: 012152/AIM.007.
35.Dashti-Khavidaki S, Talasaz AH, Tabeefar H, Hajimahmoodi M, Moghaddam G, Khalili H, Lessan-Pezeshki M, Jahanmardi A. Plasma vitamin C concentrations in patients on routine hemodialysis and its relationship to patients' morbidity and mortality. Int J Vitam Nutr Res. 2011 Jul;81(4):197-203. doi: 10.1024/0300-9831/a000065.
36.Khalili H, Talasaz AH, Salarifar M. Serum vitamin D concentration status and its correlation with early biomarkers of remodeling following acute myocardial infarction. Clin Res Cardiol. 2012 May;101(5):321-7. doi: 10.1007/s00392-011-0394-0.
37.Khalili H, Soudbakhsh A, Talasaz AH. Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. Am J Health Syst Pharm. 2011 May 15;68(10):888-92. doi: 10.2146/ajhp100516.
38.Khalili H, Dashti-Khavidaki S, Talasaz AH, Najmedin F, Hosseinpoor R. Anticoagulant utilization evaluation in a teaching hospital: a prospective study. J Pharm Pract. 2010 Dec;23(6):579-84. doi: 10.1177/0897190010372808
39.Dashti-Khavidaki S, Khalili H, Gholamalipour F, Soudbakhsh A, Talasaz AH, Hajabdolbaghi M, Rasoolinejad M, Mokhtari Azad T, Fathi M, Talebian MT, Nasiripour S. Approach to Pandemic 2009 influenza: first report from a main referral hospital for Pandemic H1N1 influenza care in Iran. J Infect Dev Ctries. 2010 Oct 28;4(10):629-35.
40.Talasaz AH, Abbasi MR, Abkhiz S, Dashti-Khavidaki S. Tribulus terrestris-induced severe nephrotoxicity in a young healthy male. Nephrol Dial Transplant. 2010 Nov;25(11):3792-3. doi: 10.1093/ndt/gfq457.
41.Khalili H, Dashti-Khavidaki S, Talasaz AH, Mahmoudi L, Eslami K, Tabeefar H. Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacists' intervention study. Pharm World Sci. 2010 Oct;32(5):594-600. doi: 10.1007/s11096-010-9412-y
42.Entezari-Maleki T,  Talasaz AH, Salarifar M, Hadjibabaie M, Javadi MR, Bozorgi A, Jenab Y, Boroumand MA, Gholami K. Plasma Vitamin D Status and Its Correlation with Risk Factors of Thrombosis, P-selectin and hs-CRP Level in Patients with Venous Thromboembolism; the First Study of Iranian Population. Iran J Pharm Res. 2014 Winter;13(1):319-27.
43.Abbasinazari M, Hajhossein Talasaz A, Mousavi Z, Zare-Toranposhti S. Evaluating the frequency of errors in preparation and administration of intravenous medications in orthopedic, general surgery and gastroenterology wards of a teaching hospital in tehran. Iran J Pharm Res. 2013 Winter;12(1):229-34.
44.Abbasinazari M, Behnava B, Panahi Y,  Talasaz AH, Salimi S, Keshvari M, Mehrnoush L, Karim Elizee P, Gholami Fesharaki M, Asgharinia M, Alavian SM. Plasma zinc level in hepatitis C patients with or without Beta thalassemia major; is there any difference? Hepat Mon. 2013 Aug 12;13(8):e11138. doi: 10.5812/hepatmon.11138. eCollection 2013.
45.Tavakoli-Ardakani M, Eshraghi A,  Talasaz AH, Salamzadeh J. A drug utilization evaluation study of amphotericin B in neutropenic patients in a teaching hospital in iran. Iran J Pharm Res. 2012 Winter;11(1):151-6.
46.Dashti-Khavidaki S, Chamani N, Khalili H,  Talasaz AH, Ahmadi F, Lessan-Pezeshki M, Ghaeli P, Dalili S, Alimadadi A. Comparing effects of clonazepam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis. 2011 Nov;5(6):404-9.
47.Talasaz AH, Khalili H, Fahimi F, Mojtaba S: Potential role of N -acetylcysteine in cardiovascular disorders. Therapy 05/2011; 8(3):237-245., DOI:10.2217/thy.11.12
48.Talasaz AH, Ghahremankhani AA, Moghadam SH, Malekshahi MR,  Atyabi F, Dinarvand R: In situ gel forming systems of poloxamer 407 and hydroxypropyl cellulose or hydroxypropyl methyl cellulose mixtures for controlled delivery of vancomycin. Journal of Applied Polymer Science 08/2008; 109(4):2369 - 2374., DOI:10.1002/app.28163



PRESENTATIONS                                        
Dashti-Khavidaki S, Tabeefar H, Talasaz AH, Hajimahmoudi M, Moghadam G, Khalili H, Jahanmardi A. (2010) Plasma vitamin C concentrations in patients on routine hemodialysis and its relationship to patients’ cardiovascular comorbidities. ESCP, Lyon, France.
Khalili H., Dashti-Khavidaki S., Talasaz AH, Mahmoudi L, Eslami K, Tabeefar H (2010). Is deep vein thrombosis prophylaxis appropriate in the medical wards: A clinical pharmacist team interventional study? ESCP, Lyon, France.
Khalili H., Dashti-Khavidaki S., Talasaz AH, Hamed Tabeefar H., Hendoiee N (2010). Descriptive Analysis of a Clinical Pharmacy Intervention to Improve the Appropriate Use of Stress Ulcer Prophylaxis in a Hospital Infectious Disease Ward. ESCP, Lyon, France.
Sahraee Z, Fahimi F, Amini S, Talasaz AH (2010). Evaluation of stat orders in a teaching hospital. ESCP, Lyon, France.
Talasaz AH (2011). Evaluating the potential effect of N-acetylcysteine on early remodeling biomarkers of ST-segment elevation myocardial infarction: A double-blind placebo controlled study. American College of Clinical Pharmacy (ACCP), Columbus, Ohio, US.
Talasaz AH (2011). Clinical Pharmacy in Iran. ACCP, Columbus, Ohio, US.
Talasaz AH, Jenab Y, Khalili H (2012).N-acetylcysteine effects on major adverse cardiac events and markers of cardiac remodeling in patients with acute myocardial infarction in one year follow up. European Society Of Cardiology (ESC). Munich, Germany.
Talasaz AH (2013). Evaluating the effect of intracoronary N-acetylcysteine on myocardial reperfusion markers following primary percutaneous coronary intervention in patients with STEMI. ESC 2013.Eur Heart J (2013) 34 (suppl 1): doi:10.1093/eurheartj/eht309.P3283
Talasaz AH (2014).The role of preoperative administration of L-carnitie in the prophylaxis of post CABG atrial fibrillation. ESC Congress, Barcelona, Spain.
Talasaz AH, Daie M, Karimi A (2017). Potential role of vitamin D supplementation in the prevention of atrial fibrillation after coronary artery bypass grafting in vitamin D deficient patients, ESC Congress, Barcelona, Spain.



AWARDS/HONORS                           

2011                                    Grant; American College of Clinical Pharmacy
2011                                    First Rank in the Board Examination- Clinical Pharmacy
2013                                Grant; European Society of Cardiology
2018                Reviewer of Heart Failure in CardSAP (ACCP)                         





تعداد بازدید :
نظرسنجی
نظر شما پيرامون کيفيت اطلاع رساني وب سايت چيست




 
مجله مرکز قلب تهران
ویژه پرسنل